- Home
- GRI vs ELWS Comparison
GRI vs ELWS Comparison
Compare GRI & ELWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ELWS
- Stock Information
- Founded
- GRI 2018
- ELWS 2018
- Country
- GRI United States
- ELWS Japan
- Employees
- GRI N/A
- ELWS N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ELWS
- Sector
- GRI Health Care
- ELWS
- Exchange
- GRI Nasdaq
- ELWS Nasdaq
- Market Cap
- GRI 6.1M
- ELWS 6.2M
- IPO Year
- GRI N/A
- ELWS 2023
- Fundamental
- Price
- GRI $0.72
- ELWS $2.94
- Analyst Decision
- GRI Strong Buy
- ELWS
- Analyst Count
- GRI 2
- ELWS 0
- Target Price
- GRI $11.50
- ELWS N/A
- AVG Volume (30 Days)
- GRI 182.9K
- ELWS 22.5K
- Earning Date
- GRI 11-14-2024
- ELWS 12-31-2024
- Dividend Yield
- GRI N/A
- ELWS N/A
- EPS Growth
- GRI N/A
- ELWS N/A
- EPS
- GRI N/A
- ELWS N/A
- Revenue
- GRI N/A
- ELWS $1,139,113.00
- Revenue This Year
- GRI N/A
- ELWS N/A
- Revenue Next Year
- GRI N/A
- ELWS N/A
- P/E Ratio
- GRI N/A
- ELWS N/A
- Revenue Growth
- GRI N/A
- ELWS 285.14
- 52 Week Low
- GRI $0.30
- ELWS $1.04
- 52 Week High
- GRI $65.00
- ELWS $13.00
- Technical
- Relative Strength Index (RSI)
- GRI 44.58
- ELWS 51.71
- Support Level
- GRI $0.68
- ELWS $2.75
- Resistance Level
- GRI $0.77
- ELWS $2.99
- Average True Range (ATR)
- GRI 0.07
- ELWS 0.20
- MACD
- GRI -0.01
- ELWS 0.00
- Stochastic Oscillator
- GRI 16.44
- ELWS 51.61
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.